Well, thank you, Carrie, and thank you all for joining us this afternoon on our Q1 2026 quarterly call. Such as casdozoketug, which we are exploring in liver cancer, and which we are exploring across ...
13h
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering ...
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through ...
Q1 2026 Management view Chairman, President & CEO Dennis Lanfear said the strategy is built around LOQTORZI as “both a revenue generator” in nasopharyngeal cancer (NPC) and “a revenue multiplier” in ...
LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results